Concorde Asset Management, LLC Bristol Myers Squibb CO Transaction History

Concorde Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$61.91 - $67.42 $355,177 - $386,788	-5,737 Closed	0 $0
Q1 2021 Apr 27, 2021	BUY	$59.34 - $66.74 $49,133 - $55,260	828 Added 16.87%	5,737 $361,000
Q4 2020 Jan 29, 2021	SELL	$57.74 - $65.43 $1,097 - $1,243	-19 Reduced 0.39%	4,909 $305,000
Q3 2020 Oct 23, 2020	BUY	$57.43 - $63.64 $283,015 - $313,617	4,928 New	4,928 $296,000
Q2 2020 Jul 20, 2020	SELL	$54.82 - $64.09 $250,472 - $292,827	-4,569 Closed	0 $0
Q1 2020 Apr 22, 2020	BUY	$46.4 - $67.43 $212,001 - $308,087	4,569 New	4,569 $255,000
Q4 2017 Jan 23, 2018	SELL	$59.94 - $65.35 $199,720 - $217,746	-3,332 Closed	0 $0
Q3 2017 Oct 31, 2017	BUY	$55.23 - $63.74 $184,026 - $212,381	3,332	3,332 $212,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Concorde Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Concorde Asset Management, LLC with notifications on news.